menu
Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated >>Roots>>
Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated >>Roots>>
Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated

Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated

Encouragingclinical results across various metabolic, hematological and ophthalmicdisorders have inspired research groups across the world to focus their effortson the development of novel gene editing therapies. In fact, the gene therapy pipelinehas evolved significantly over the past few years, with three products beingapproved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis)and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates inmid to late-stage (phase II and above) trials that are anticipated to enter themarket over the next 5-10 years.

 

To order this 670+ page report, which features 190+ figuresand 340+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

The USD 11.6 billion (by 2030) financialopportunity within the gene therapy market has been analyzed across thefollowing segments:

§ Key therapeutic areas

§ Autoimmune disorders

§ Cardiovascular diseases

§ Genetic disorders

§ Hematologicaldisorders

§ Metabolic disorders

§ Ophthalmic disorders

§ Oncological disorders

§ Others

 

§ Type of vector

§ Adeno associatedvirus

§ Adenovirus

§ Herpes simplex virustype 1

§ Lentivirus

§ Plasmid DNA

§ Retrovirus

§ Vaccinia Virus

 

§ Type of therapy

§ Exvivo

§ In vivo

 

§ Type of genemodification

§ Gene augmentation

§ Immunotherapy

§ Oncolytic therapy

§ Others

 

§ Route ofadministration

§ Intraarticular

§ Intracerebellar

§ Intramuscular

§ Intradermal

§ Intravenous

§ Intravitreal

§ Intravesical

§ Subretinal

§ Others

 

§ Key geographicalregions

§ North America

§ Europe

§ Asia-Pacific

 

The Gene Therapy Market (3rd Edition), 2019-2030 reportfeatures the following companies, which we identified to be key players in thisdomain:

§ Advantagene

§ Advaxis

§ BioMarin

§ bluebird bio

§ FKD Therapies

§ Freeline Therapeutics

§ GenSight Biologics

§ Gradalis

§ InovioPharmaceuticals

§ Marsala Biotech

§ Orchard Therapeutics

§ Pfizer

§ Sarepta Therapeutics

§ Spark Therapeutics

§ Tocagen

§ Transgene

§ uniQure Biopharma

§ VBL Therapeutics

§ ViroMed

 

Table of Contents

 

1. Preface

 

2. Executive Summary

 

3. Introduction

 

4. Gene Delivery Vectors

 

5. Regulatory Landscape and ReimbursementScenario

 

6. Competitive Landscape

 

7. Marketed Gene Therapies

 

8. Key Commercialization Strategies

 

9. Late Stage (Phase II/III and Above) GeneTherapies

 

10. Emerging Technologies

 

11. Promising Therapeutics Areas

 

12. Patent Analysis

 

13. Mergers and Acquisitions

 

14. Funding and Investment Analysis

 

15. Cost Price Analysis

 

16. Big Pharma Players: Analysis of GeneTherapy Related Initiatives

 

17. Market Forecast and Opportunity Analysis

 

18. Vector Manufacturing

 

19. Case Study: Gene Therapy Supply Chain

 

20. Conclusion

 

21. Interview Transcripts

 

22. Appendix 1: Tabulated Data

 

23. Appendix 2: List of Companies and Organizations

 

Topurchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

 

ContactDetails

GauravChaudhary

+1(415) 800 3415

gaurav.chaudhary@rootsanalysis.com